To confirm that key pro-survival proteins targeted by BH3-mimetics (BCL-2, BCL-XL, MCL-1) were expressed in more clinically-relevant patient-derived tissue, we performed immunohistochemistry on 127 biopsies from melanoma patients with Stage III/IV disease (Fig. 1b). This evidence concerns the gene BCL2 and melanoma.